Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 11.8 SGD -0.59% Market Closed
Market Cap: 2.6B SGD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one H02 stock under the Base Case scenario is 6.61 SGD. Compared to the current market price of 11.8 SGD, Haw Par Corporation Ltd is Overvalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

H02 Relative Value
Base Case
6.61 SGD
Overvaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.7
P/S
P/S
Price to Sales
10.7
vs History
66
vs Industry
12
Median 3Y
11
Median 5Y
11.5
Industry
2.6
More Details
11.4
P/E
P/E
Price to Earnings
11.4
vs History
71
vs Industry
35
Median 3Y
12.3
Median 5Y
12.8
Industry
21.5
More Details
48.6
P/OCF
P/OCF
Price to OCF
48.6
vs History
52
vs Industry
8
Median 3Y
48.3
Median 5Y
51
Industry
16.6
More Details
46.5
P/FCFE
P/FCFE
Price to FCFE
46.5
vs History
61
vs Industry
11
Median 3Y
45.5
Median 5Y
53.9
Industry
24
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
66
vs Industry
68
Median 3Y
0.6
Median 5Y
0.7
Industry
2.1
More Details
7.8
EV/S
EV/S
Enterprise Value to Sales
7.8
vs History
69
vs Industry
15
Median 3Y
8.9
Median 5Y
9.6
Industry
2.7
More Details
14.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.2
vs History
68
vs Industry
13
Median 3Y
16.5
Median 5Y
17.4
Industry
5.3
More Details
26.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26.7
vs History
61
vs Industry
36
Median 3Y
31.5
Median 5Y
33.4
Industry
12.8
More Details
29.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.2
vs History
61
vs Industry
40
Median 3Y
35
Median 5Y
37.1
Industry
16.2
More Details
35.4
EV/OCF
EV/OCF
Enterprise Value to OCF
35.4
vs History
61
vs Industry
10
Median 3Y
40.8
Median 5Y
42.1
Industry
14.9
More Details
37.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
37.8
vs History
61
vs Industry
12
Median 3Y
74.9
Median 5Y
82
Industry
17.7
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
77
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9
More Details

Multiples Across Competitors

H02 Competitors Multiples
Haw Par Corporation Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Haw Par Corporation Ltd
SGX:H02
2.6B SGD 10.7 11.4 26.7 29.2
US
Eli Lilly and Co
NYSE:LLY
776.5B USD 15.8 69.9 37.5 41
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.9B USD 4.2 17.3 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.3
CH
Roche Holding AG
SIX:ROG
214.5B CHF 3.5 25.9 9.7 11.4
CH
Novartis AG
SIX:NOVN
190.4B CHF 4.4 18.3 10.7 14.4
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 4.2 29.7 131.4 198.1
US
Merck & Co Inc
NYSE:MRK
205.6B USD 3.2 11.8 8.8 10.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
139.5B USD 2.2 17.7 7.6 10.7
P/E Multiple
Earnings Growth PEG
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 24.9
11.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
69.9
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.7
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBITDA: 397.1
26.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.7
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.4
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBIT: 1 700.6
29.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1

See Also

Summary
H02 intrinsic value, competitors valuation, and company profile.
DCF Valuation
H02 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
H02 stock valuation using valuation multiples.
Wall Street Estimates
H02 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
H02 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.